Leerink analyst Andrew Berens raised the firm’s price target on Cogent Biosciences (COGT) to $50 from $18 and keeps an Outperform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback